TCF4 gene polymorphism and cognitive performance in patients with first episode psychosis.
|Title||TCF4 gene polymorphism and cognitive performance in patients with first episode psychosis.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Albanna A, Choudhry Z, Harvey P-O, Fathalli F, Cassidy C, Sengupta SM, Iyer SN, Rho A, Lepage M, Malla A, Joober R|
|Date Published||2014 Jan|
|Keywords||Adolescent, Adult, Analysis of Variance, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Cognition Disorders, Female, Humans, Male, Neuropsychological Tests, Polymorphism, Single Nucleotide, Problem Solving, Psychiatric Status Rating Scales, Psychotic Disorders, Retrospective Studies, Transcription Factors, Young Adult|
BACKGROUND: Single nucleotide polymorphisms in TCF4 gene have been consistently associated with schizophrenia in genome wide association studies, including the C allele of rs9960767. However, its exact role in modulating the schizophrenia phenotype is not known.AIMS: To comprehensively investigate the relationship between rs9960767 risk allele (C) of TCF4 and cognitive performance in patients with first episode psychosis (FEP).METHODS: 173 patients with FEP received a comprehensive neurocognitive evaluation and were genotyped for rs9960767. Carriers of the risk allele (CA/CC) were compared to non-carriers (AA) using Multivariate Analysis of Covariance MANCOVA. Ethnicity, negative symptoms and substance abuse were included as covariates.RESULTS: Carriers of the risk allele had a statistically significant lower performance in the cognitive domain of Reasoning/Problem-Solving compared to non-carriers (F1,172=4.4, p=.038). There were no significant genotype effects on the other cognitive domains or general cognition. This effect on the Reasoning/Problem-Solving domain remained significant even when controlling for IQ (F1,172=4.3, p=.039).CONCLUSIONS: rs9960767 (C) of TCF4 appears to be associated with neurocognitive deficits in the Reasoning/Problem-Solving cognitive domain, in patients with FEP. A confirmation of this finding in a larger sample and including other TCF4 polymorphisms will be needed to gain further validity of this result.
|Alternate Journal||Schizophr. Res.|
|Grant List||/ / Canadian Institutes of Health Research / Canada|